Report cover image

Global Age Related Macular Degeneration Drug Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 194 Pages
SKU # APRC20284010

Description

Summary

According to APO Research, The global Age Related Macular Degeneration Drug market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Age Related Macular Degeneration Drug is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Age Related Macular Degeneration Drug include Bayer HealthCare, Kanghong Pharma, Regeneron Pharmaceuticals, Roche and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Age Related Macular Degeneration Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Age Related Macular Degeneration Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Age Related Macular Degeneration Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Age Related Macular Degeneration Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Age Related Macular Degeneration Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Age Related Macular Degeneration Drug sales, projected growth trends, production technology, application and end-user industry.

Age Related Macular Degeneration Drug Segment by Company

Bayer HealthCare
Kanghong Pharma
Regeneron Pharmaceuticals
Roche
Novartis
Age Related Macular Degeneration Drug Segment by Type

Eylea
Avastin
Lucentis
Others
Age Related Macular Degeneration Drug Segment by Application

Hospitals
Clinics
Others
Age Related Macular Degeneration Drug Segment by Region

North America
United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Age Related Macular Degeneration Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Age Related Macular Degeneration Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Age Related Macular Degeneration Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Age Related Macular Degeneration Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Age Related Macular Degeneration Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Age Related Macular Degeneration Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Age Related Macular Degeneration Drug Market by Type
1.2.1 Global Age Related Macular Degeneration Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Eylea
1.2.3 Avastin
1.2.4 Lucentis
1.2.5 Others
1.3 Age Related Macular Degeneration Drug Market by Application
1.3.1 Global Age Related Macular Degeneration Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Age Related Macular Degeneration Drug Market Dynamics
2.1 Age Related Macular Degeneration Drug Industry Trends
2.2 Age Related Macular Degeneration Drug Industry Drivers
2.3 Age Related Macular Degeneration Drug Industry Opportunities and Challenges
2.4 Age Related Macular Degeneration Drug Industry Restraints
3 Global Market Growth Prospects
3.1 Global Age Related Macular Degeneration Drug Revenue Estimates and Forecasts (2020-2031)
3.2 Global Age Related Macular Degeneration Drug Revenue by Region
3.2.1 Global Age Related Macular Degeneration Drug Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global Age Related Macular Degeneration Drug Revenue by Region (2020-2025)
3.2.3 Global Age Related Macular Degeneration Drug Revenue by Region (2026-2031)
3.2.4 Global Age Related Macular Degeneration Drug Revenue Market Share by Region (2020-2031)
3.3 Global Age Related Macular Degeneration Drug Sales Estimates and Forecasts 2020-2031
3.4 Global Age Related Macular Degeneration Drug Sales by Region
3.4.1 Global Age Related Macular Degeneration Drug Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global Age Related Macular Degeneration Drug Sales by Region (2020-2025)
3.4.3 Global Age Related Macular Degeneration Drug Sales by Region (2026-2031)
3.4.4 Global Age Related Macular Degeneration Drug Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global Age Related Macular Degeneration Drug Revenue by Manufacturers
4.1.1 Global Age Related Macular Degeneration Drug Revenue by Manufacturers (2020-2025)
4.1.2 Global Age Related Macular Degeneration Drug Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global Age Related Macular Degeneration Drug Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global Age Related Macular Degeneration Drug Sales by Manufacturers
4.2.1 Global Age Related Macular Degeneration Drug Sales by Manufacturers (2020-2025)
4.2.2 Global Age Related Macular Degeneration Drug Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global Age Related Macular Degeneration Drug Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global Age Related Macular Degeneration Drug Sales Price by Manufacturers (2020-2025)
4.4 Global Age Related Macular Degeneration Drug Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global Age Related Macular Degeneration Drug Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Age Related Macular Degeneration Drug Manufacturers, Product Type & Application
4.7 Global Age Related Macular Degeneration Drug Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global Age Related Macular Degeneration Drug Market CR5 and HHI
4.8.2 2024 Age Related Macular Degeneration Drug Tier 1, Tier 2, and Tier 3
5 Age Related Macular Degeneration Drug Market by Type
5.1 Global Age Related Macular Degeneration Drug Revenue by Type
5.1.1 Global Age Related Macular Degeneration Drug Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global Age Related Macular Degeneration Drug Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Type (2020-2031)
5.2 Global Age Related Macular Degeneration Drug Sales by Type
5.2.1 Global Age Related Macular Degeneration Drug Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global Age Related Macular Degeneration Drug Sales by Type (2020-2031) & (W Units)
5.2.3 Global Age Related Macular Degeneration Drug Sales Market Share by Type (2020-2031)
5.3 Global Age Related Macular Degeneration Drug Price by Type
6 Age Related Macular Degeneration Drug Market by Application
6.1 Global Age Related Macular Degeneration Drug Revenue by Application
6.1.1 Global Age Related Macular Degeneration Drug Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global Age Related Macular Degeneration Drug Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global Age Related Macular Degeneration Drug Revenue Market Share by Application (2020-2031)
6.2 Global Age Related Macular Degeneration Drug Sales by Application
6.2.1 Global Age Related Macular Degeneration Drug Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global Age Related Macular Degeneration Drug Sales by Application (2020-2031) & (W Units)
6.2.3 Global Age Related Macular Degeneration Drug Sales Market Share by Application (2020-2031)
6.3 Global Age Related Macular Degeneration Drug Price by Application
7 Company Profiles
7.1 Bayer HealthCare
7.1.1 Bayer HealthCare Comapny Information
7.1.2 Bayer HealthCare Business Overview
7.1.3 Bayer HealthCare Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio
7.1.5 Bayer HealthCare Recent Developments
7.2 Kanghong Pharma
7.2.1 Kanghong Pharma Comapny Information
7.2.2 Kanghong Pharma Business Overview
7.2.3 Kanghong Pharma Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio
7.2.5 Kanghong Pharma Recent Developments
7.3 Regeneron Pharmaceuticals
7.3.1 Regeneron Pharmaceuticals Comapny Information
7.3.2 Regeneron Pharmaceuticals Business Overview
7.3.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio
7.3.5 Regeneron Pharmaceuticals Recent Developments
7.4 Roche
7.4.1 Roche Comapny Information
7.4.2 Roche Business Overview
7.4.3 Roche Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Roche Age Related Macular Degeneration Drug Product Portfolio
7.4.5 Roche Recent Developments
7.5 Novartis
7.5.1 Novartis Comapny Information
7.5.2 Novartis Business Overview
7.5.3 Novartis Age Related Macular Degeneration Drug Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Novartis Age Related Macular Degeneration Drug Product Portfolio
7.5.5 Novartis Recent Developments
8 North America
8.1 North America Age Related Macular Degeneration Drug Market Size by Type
8.1.1 North America Age Related Macular Degeneration Drug Revenue by Type (2020-2031)
8.1.2 North America Age Related Macular Degeneration Drug Sales by Type (2020-2031)
8.1.3 North America Age Related Macular Degeneration Drug Price by Type (2020-2031)
8.2 North America Age Related Macular Degeneration Drug Market Size by Application
8.2.1 North America Age Related Macular Degeneration Drug Revenue by Application (2020-2031)
8.2.2 North America Age Related Macular Degeneration Drug Sales by Application (2020-2031)
8.2.3 North America Age Related Macular Degeneration Drug Price by Application (2020-2031)
8.3 North America Age Related Macular Degeneration Drug Market Size by Country
8.3.1 North America Age Related Macular Degeneration Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America Age Related Macular Degeneration Drug Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America Age Related Macular Degeneration Drug Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Age Related Macular Degeneration Drug Market Size by Type
9.1.1 Europe Age Related Macular Degeneration Drug Revenue by Type (2020-2031)
9.1.2 Europe Age Related Macular Degeneration Drug Sales by Type (2020-2031)
9.1.3 Europe Age Related Macular Degeneration Drug Price by Type (2020-2031)
9.2 Europe Age Related Macular Degeneration Drug Market Size by Application
9.2.1 Europe Age Related Macular Degeneration Drug Revenue by Application (2020-2031)
9.2.2 Europe Age Related Macular Degeneration Drug Sales by Application (2020-2031)
9.2.3 Europe Age Related Macular Degeneration Drug Price by Application (2020-2031)
9.3 Europe Age Related Macular Degeneration Drug Market Size by Country
9.3.1 Europe Age Related Macular Degeneration Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe Age Related Macular Degeneration Drug Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe Age Related Macular Degeneration Drug Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Netherlands
9.3.9 Nordic Countries
10 China
10.1 China Age Related Macular Degeneration Drug Market Size by Type
10.1.1 China Age Related Macular Degeneration Drug Revenue by Type (2020-2031)
10.1.2 China Age Related Macular Degeneration Drug Sales by Type (2020-2031)
10.1.3 China Age Related Macular Degeneration Drug Price by Type (2020-2031)
10.2 China Age Related Macular Degeneration Drug Market Size by Application
10.2.1 China Age Related Macular Degeneration Drug Revenue by Application (2020-2031)
10.2.2 China Age Related Macular Degeneration Drug Sales by Application (2020-2031)
10.2.3 China Age Related Macular Degeneration Drug Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Age Related Macular Degeneration Drug Market Size by Type
11.1.1 Asia Age Related Macular Degeneration Drug Revenue by Type (2020-2031)
11.1.2 Asia Age Related Macular Degeneration Drug Sales by Type (2020-2031)
11.1.3 Asia Age Related Macular Degeneration Drug Price by Type (2020-2031)
11.2 Asia Age Related Macular Degeneration Drug Market Size by Application
11.2.1 Asia Age Related Macular Degeneration Drug Revenue by Application (2020-2031)
11.2.2 Asia Age Related Macular Degeneration Drug Sales by Application (2020-2031)
11.2.3 Asia Age Related Macular Degeneration Drug Price by Application (2020-2031)
11.3 Asia Age Related Macular Degeneration Drug Market Size by Country
11.3.1 Asia Age Related Macular Degeneration Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia Age Related Macular Degeneration Drug Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia Age Related Macular Degeneration Drug Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Age Related Macular Degeneration Drug Market Size by Type
12.1.1 SAMEA Age Related Macular Degeneration Drug Revenue by Type (2020-2031)
12.1.2 SAMEA Age Related Macular Degeneration Drug Sales by Type (2020-2031)
12.1.3 SAMEA Age Related Macular Degeneration Drug Price by Type (2020-2031)
12.2 SAMEA Age Related Macular Degeneration Drug Market Size by Application
12.2.1 SAMEA Age Related Macular Degeneration Drug Revenue by Application (2020-2031)
12.2.2 SAMEA Age Related Macular Degeneration Drug Sales by Application (2020-2031)
12.2.3 SAMEA Age Related Macular Degeneration Drug Price by Application (2020-2031)
12.3 SAMEA Age Related Macular Degeneration Drug Market Size by Country
12.3.1 SAMEA Age Related Macular Degeneration Drug Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA Age Related Macular Degeneration Drug Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA Age Related Macular Degeneration Drug Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 Age Related Macular Degeneration Drug Value Chain Analysis
13.1.1 Age Related Macular Degeneration Drug Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Age Related Macular Degeneration Drug Production Mode & Process
13.2 Age Related Macular Degeneration Drug Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Age Related Macular Degeneration Drug Distributors
13.2.3 Age Related Macular Degeneration Drug Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.